NCT00401596View on ClinicalTrials.gov

A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,899

Participants

Timeline

Start Date

July 31, 2000

Study Completion Date

July 31, 2002

Conditions
Asthma
Interventions
DRUG

Xolair (omalizumab)

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY